US › Healthcare

Galmed Pharmaceuticals Ltd (GLMD)

US · Healthcare · Biotechnology

$0.58-1.64%

Last close · 2026-08-04

Latest quarter · ended 2026-06-30

Net profit

$-1.9M

Profit YoY

+23.4%

EPS

$-0.29

EPS estimate

$-0.38

EPS came in at -0.29 against a street estimate of -0.38 — a beat of 23.7%.

Key statistics

Market cap

$5.1M

Forward P/E

0.0

P/B

0.36

Book value

$2.11

EPS (TTM)

$-2.06

52-week high

$1.70

52-week low

$0.41

50-day MA

$0.59

200-day MA

$0.76

Beta

0.74

Analyst view

Analysts rate Galmed Pharmaceuticals Ltd a hold (0 buy, 1 hold, 0 sell out of 1) with an average price target of $12.00.

Shareholding

Insiders

3.06%

Institutions

1.79%

Largest institutional holders

Fund	Stake
Two Sigma Investments LLC	1.04%
Two Sigma Advisers, LLC	0.41%
XTX Topco Ltd	0.29%
Jane Street Group LLC	0.21%
TWO SIGMA SECURITIES, LLC	0.16%
Citadel Advisors Llc	0.15%
UBS Group AG	0.03%
BNP Paribas Arbitrage, SA	0.01%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Galmed Pharmaceuticals Ltd — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Novo Nordisk A/S Amgen Inc Abbott Laboratories Gilead Sciences Inc

Data updated 2026-08-05.